\u0160odien, 27. febru\u0101r\u012b akciju sabiedr\u012bbas Grindeks \u201eNASDAQ Riga\u201d iesniegtie 2014. gada nerevid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati liecina, ka 2014. gadu Koncerns nosl\u0113dza ar 2,3 milj.euro zaud\u0113jumiem, kas attiecin\u0101mi uz m\u0101tes sabiedr\u012bbas akcion\u0101riem. Sal\u012bdzino\u0161i 2013. gad\u0101 koncerna neto pe\u013c\u0146a bija 13,5 milj. euro. Koncerna apgroz\u012bjums 2014. gad\u0101 bija 88,4 milj. euro, kas ir par 30 milj. euro vai par 25% maz\u0101k nek\u0101 2013. gad\u0101. Koncerna bruto pe\u013c\u0146as rentabilit\u0101te 2014. gad\u0101 bija 54%, savuk\u0101rt t\u012br\u0101s pe\u013c\u0146as rentabilit\u0101te bija -2,6%.<\/p>\n\n\n\n
2014. gad\u0101 Koncerna sara\u017eot\u0101 produkcija eksport\u0113ta uz 60 pasaules valst\u012bm, kopum\u0101 par 83 milj. euro, kas ir par 29,3 milj. euro vai par 26% maz\u0101k nek\u0101 2013. gad\u0101. \u0122eopolitisk\u0101 situ\u0101cija Krievij\u0101 un Ukrain\u0101 ir galvenais Koncerna darb\u012bbas r\u0101d\u012bt\u0101ju ietekm\u0113jo\u0161ais faktors. Liel\u0101k\u0101 da\u013ca Koncerna zaud\u0113jumu ir saist\u0101ma ar dramatisko Krievijas rub\u013ca v\u0113rt\u012bbas kritumu, kura rezult\u0101t\u0101 uz\u0146\u0113muma neieg\u016bt\u0101 pe\u013c\u0146a veido vismaz 6,2 milj. euro.<\/p>\n\n\n\n
P\u0101rskata perioda beig\u0101s debitoru par\u0101du apjoms veidoja 56,2 milj. euro<\/em>, kas ir par 9 milj. euro<\/em>vair\u0101k nek\u0101 kreditoru apjoms, kas veidoja 47,3 milj. euro<\/em>. Kreditoru saist\u012bb\u0101s iek\u013cauti ar\u012b 9 milj.euro<\/em> par dividend\u0113m, kas tiks izmaks\u0101tas 2015. gada 10. mart\u0101. Savuk\u0101rt apgroz\u0101mo l\u012bdzek\u013cu apjoms p\u0101rskata perioda beig\u0101s bija 77,5 milj. euro<\/em>, kas par 42 milj. euro<\/em> p\u0101rsniedza \u012bstermi\u0146a kreditoru apjomu, kas bija 35,4 milj. euro<\/em> apjom\u0101. J\u0101\u0146em v\u0113r\u0101, ka \u0123eopolitisk\u0101 situ\u0101cija Krievij\u0101 un Ukrain\u0101 ietekm\u0113 ne tikai Latvijas, bet ar\u012b citu valstu farm\u0101cijas nozares uz\u0146\u0113mumus, taj\u0101 skait\u0101 ar\u012b Grindeks sadarb\u012bbas partnerus. Noteikt\u0101 m\u0113r\u0101 tas atsaucas ar\u012b uz naudas pl\u016bsmu, ta\u010du kop\u0113jo finan\u0161u situ\u0101ciju Grindeks v\u0113rt\u0113 k\u0101 stabilu.<\/p>\n\n\n\n Grindeks gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms 2014. gad\u0101 bija 78,9 milj. euro<\/em> un ir samazin\u0101jies, sal\u012bdzinot ar 2013. gadu, par 21,4 milj. euro<\/em> vai 21%. Galvenie gatavo z\u0101\u013cu tirgi bija Krievija, p\u0101r\u0113j\u0101s NVS valstis, Gruzija un Baltijas valstis. Krievijas, p\u0101r\u0113jo NVS valstu un Gruzijas p\u0101rdo\u0161anas apjoms 2014. gad\u0101 sasniedza 60,5 milj. euro<\/em>, kas ir par 26,2 milj. euro<\/em> vai 30% maz\u0101k nek\u0101 2013. gad\u0101. Augst\u0101ko pieaugumu, sal\u012bdzinot ar 2013.gadu, uzr\u0101d\u012bja Arm\u0113nija +50%, Baltkrievija +21%, Azerbaid\u017e\u0101na +17%, un Turkmenist\u0101na +12%. Savuk\u0101rt gatavo z\u0101\u013cu formu p\u0101rdo\u0161anas apjoms Baltijas un cit\u0101s valst\u012bs sasniedza 18,4 milj. euro<\/em>, kas ir par 4,8 milj.euro<\/em> vai 36% vair\u0101k nek\u0101 2013. gad\u0101. 2014. gad\u0101 Grindeks ir uzs\u0101cis gatavo z\u0101\u013cu eksportu uz vair\u0101kiem jauniem tirgiem \u2013 Lielbrit\u0101niju, Somiju, Slov\u0101kiju, Sp\u0101niju, N\u012bderlandi un Portug\u0101li. 2014.gad\u0101 sekm\u012bgi turpin\u0101j\u0101s sadarb\u012bba ar Tunisiju, palielinot p\u0101rdo\u0161anas apjomu 2,7 reizes, sal\u012bdzinot ar 2013. gadu, Vjetnamu, palielinot p\u0101rdo\u0161anas apjomu 4,3 reizes, Rum\u0101niju, palielinot p\u0101rdo\u0161anas apjomu 3 reizes. Tirgos, kas atrodas \u0101rpus NVS un Baltijas valst\u012bm, apgroz\u012bjums 2014. gad\u0101, sal\u012bdzinot ar 2013. gadu, ir palielin\u0101jies 3,7 reizes.<\/p>\n\n\n\n 2014. gad\u0101 akt\u012bvo farmaceitisko vielu p\u0101rdo\u0161anas apjoms sasniedza 9 milj. euro<\/em>, kas ir par 8,9 milj. euro<\/em> vai 50% maz\u0101k nek\u0101 2013. gad\u0101. Galvenie Grindeks akt\u012bvo farmaceitisko vielu eksporta tirgi 2014. gad\u0101 bija N\u012bderlande, V\u0101cija, Kan\u0101da, ASV, Francija, \u012arija un Jap\u0101na. Grindeks piepras\u012bt\u0101k\u0101s akt\u012bv\u0101s farmaceitisk\u0101s vielas 2014. gad\u0101 bija zopiklons, oksitoc\u012bns, ftoraf\u016brs, droperidols, ksilaz\u012bns, medetomid\u012bns, detomid\u012bns un UDHS.<\/p>\n\n\n\n Neskatoties uz nelabv\u0113l\u012bgo situ\u0101ciju galvenajos gatavo z\u0101\u013cu tirgos, 2014. gad\u0101 Koncerns turpin\u0101ja strat\u0113\u0123iski svar\u012bg\u0101kos p\u0113tniec\u012bbas un att\u012bst\u012bbas projektus. Sadarb\u012bb\u0101 ar Latvijas zin\u0101tniekiem sekm\u012bgi pabeigti kardioprotekt\u012bv\u0101s vielas \u2013 GBB hidroksil\u0101zes inhibitora ar ori\u0123in\u0101lu strukt\u016bru \u2013 \u0137\u012bmiskie un prekl\u012bniskie farmakolo\u0123isk\u0101s efektivit\u0101tes p\u0113t\u012bjumi, kas ir noz\u012bm\u012bgs posms jauna medic\u012bnas prepar\u0101ta rad\u012b\u0161an\u0101. Otrs projekts ir medikamenta Mildron\u0101ts\u00ae<\/small> re\u0123istr\u0101cija \u0136\u012bn\u0101, kur \u0161obr\u012bd tiek veikts prepar\u0101ta 3. f\u0101zes kl\u012bniskais p\u0113t\u012bjums.<\/p>\n\n\n\n AS Grindeks valdes priek\u0161s\u0113d\u0113t\u0101js Juris Bundulis: \u201e\u0145emot v\u0113r\u0101 Grindeks pieredzi biznesa organiz\u0101cij\u0101 60 pasaules valst\u012bs, uz\u0146\u0113mums ir p\u0101rliecin\u0101ts, ka biznesa diversifik\u0101cija un m\u0113r\u0137tiec\u012bga darb\u012bbas p\u0101rstrukturiz\u0101cija, nes\u012bs pozit\u012bvu rezult\u0101tu. N\u0101kamaj\u0101 period\u0101 Grindeks aizvien vair\u0101k koncentr\u0113sies uz jaunajiem tirgiem, diversific\u0113jot savu darb\u012bbu un samazinot riskus. Uz\u0146\u0113mums ar\u012b iepriek\u0161 ir sask\u0101ries ar da\u017e\u0101d\u0101m kr\u012bzes situ\u0101cij\u0101m un sp\u0113jis profesion\u0101li koncentr\u0113t savas zin\u0101\u0161anas un resursus, lai \u0161\u0137\u0113r\u0161\u013cus p\u0101rvar\u0113tu.\u201d<\/p>\n\n\n\n <\/a>Nerevid\u0113ts Grindeks 2014. gada 12 m\u0113ne\u0161u finan\u0161u p\u0101rskats (423 KB)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" \u0160odien, 27. febru\u0101r\u012b akciju sabiedr\u012bbas Grindeks \u201eNASDAQ Riga\u201d iesniegtie 2014. gada nerevid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati liecina, ka 2014. gadu Koncerns nosl\u0113dza ar 2,3 milj.euro zaud\u0113jumiem,…<\/p>\n","protected":false},"author":3,"featured_media":6601,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-1545","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/1545","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=1545"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/1545\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/6601"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=1545"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=1545"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=1545"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}